Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact on a clinically meaningful endpoint—that is, an endpoint that directly measures how a patient feels (symptoms), functions (the ability to perform activities in daily life), or survives. In idiopathic pul...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Respir Crit Care Med
Autori principali: Raghu, Ganesh, Collard, Harold R., Anstrom, Kevin J., Flaherty, Kevin R., Fleming, Thomas R., King, Talmadge E., Martinez, Fernando J., Brown, Kevin K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Thoracic Society 2012
Soggetti:
Pulmonary Perspective
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448580/
https://ncbi.nlm.nih.gov/pubmed/22505745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201201-0006PP
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi